A5082352351- Immunotherapy and Immune Responses
- RNA Interference and Gene Delivery
- Cancer Immunotherapy and Biomarkers
- T-cell and B-cell Immunology
- Immune Cell Function and Interaction
- vaccines and immunoinformatics approaches
- CAR-T cell therapy research
- Immune Response and Inflammation
- Monoclonal and Polyclonal Antibodies Research
- Transgenic Plants and Applications
- Chemokine receptors and signaling
- Immune cells in cancer
- Dendrimers and Hyperbranched Polymers
- Neuroendocrine regulation and behavior
- Cancer Cells and Metastasis
- Cell death mechanisms and regulation
- Dermatology and Skin Diseases
- Lipid Membrane Structure and Behavior
- Circadian rhythm and melatonin
- Computational Drug Discovery Methods
- Chemical Synthesis and Analysis
Queen Mary University of London
2017-2023
Charité - Universitätsmedizin Berlin
2013-2017
Universidade de São Paulo
2008-2013
Humboldt-Universität zu Berlin
2013
Freie Universität Berlin
2013
Universidade Cidade de São Paulo
2008
In recent years immune checkpoint inhibitors have garnered attention as being one of the most promising types immunotherapy on horizon. There has been particular focus molecules, cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed cell death protein 1 (PD-1) which shown to potent immunomodulatory effects through their function negative regulators T activation. CTLA-4, engagement with its ligands B7-1 (CD80) B7-2 (CD86), plays a pivotal role in attenuating activation naïve memory cells....
MHC class II expression is a hallmark of professional antigen-presenting cells and key to the induction CD4+ T helper cells. We found that these molecules are ectopically expressed on tumor in large proportion patients with pancreatic ductal adenocarcinoma (PDAC) several PDAC cell lines. In contrast previous reports tumoral MHC-II melanoma enabled evade immunosurveillance, neither protected cancer from Fas-mediated death nor caused T-cell suppression by engagement its ligand LAG-3 activated...
Triple-negative breast cancer (TNBC) corresponds to approximately 20% of all tumors, with a high propensity for metastasis and poor prognosis. Because TNBC displays mutational load compared other types, neoantigen-based immunotherapy strategy could be effective. One major bottleneck in the development vaccine is selection best targets, that is, tumor-specific neoantigens which are presented at surface tumor cells capable eliciting robust immune responses. In this study, we aimed set up...
This study evaluated the effects of cohabitation with a B16F10 melanoma-bearer cage mate on behavior and immune functions in mice. Five different experiments were conducted. In each them, female mice divided into two groups: control experimental. One mouse pair was kept undisturbed called "companion health partner" (CHP). experimental inoculated cells other, subject this study, sick (CSP). On Day 20 cohabitation, parameters from CHP CSP analyzed. comparison to CHP, mice: (1) presented an...
Background: Prioritizing building blocks for combinatorial medicinal chemistry represents an optimization task. We present the application of artificial ant colony algorithm to molecular design (Molecular Ant Algorithm [MAntA]). Results: In a retrospective evaluation, performed favorably compared with other stochastic methods. Application MAntA peptide resulted in new octapeptides exhibiting substantial binding mouse MHC-I (H-2Kb). second study, generated functional factor Xa inhibitor by...
The induction of effective T cell-mediated immune responses is the main objective vaccination against cancer. cell are initiated by dendritic cells (DCs) as most potent antigen-presenting cells. Designing vaccines for efficient delivery tumor antigens to these in immunogenic fashion is, therefore, a major task immunology. In this human-based vitro study we investigated suitability different polymeric nanoparticles (NPs) delivering tumor-associated antigen Her2/neu DCs mucosal vaccination....
We present the development and application of a new machine-learning approach to exhaustively reliably identify major histocompatibility complex class I (MHC-I) ligands among all 208 octapeptides in genome-derived proteomes Mus musculus, influenza A H3N8, vesicular stomatitis virus (VSV). Focusing on murine H-2Kb, we identified potent exhibiting direct MHC-I binding stabilization surface TAP-deficient RMA-S cells. Computationally VSV-derived peptides induced CD8+ T-cell proliferation after...
Dendritic cells (DCs) are key activators of cellular immune responses through their capacity to induce naïve T and sustained effector cell responses. This is a function superior efficiency antigen presentation via MHC class I II molecules, the expression co-stimulatory surface molecules cytokines. Maturation DCs induced by microbial factors pattern recognition receptors such as Toll-like receptors, pro-inflammatory cytokines or cognate interaction with CD4+ cells. Here we show that,...
Cross-presentation is the process by which professional antigen presenting cells (APCs) (B cells, dendritic (DCs) and macrophages) present endocytosed antigens (Ags) via MHC-I to CD8+ T cells. This crucial for induction of adaptive immune responses against tumors infected The pathways cellular compartments involved in cross-presentation are unresolved controversial. Among with cross-presenting capacity, DCs most efficient, was proposed depend on prevention endosomal acidification block...
Abstract Dendritic cells (DCs) and macrophages are specialized APCs that process present self-Ags for induction of tolerance foreign Ags to initiate T cell–mediated immunity. Related differentiation states they have specific phenotypes functions. However, the impact these differentiations on Ag processing presentation remains poorly defined. To gain insight into this, we analyzed compared HLA-I peptidomes MUTZ3-derived human immature mature DC lines THP1-derived by liquid chromatography...
RAS mutations occur in approximately 20% of all cancers and given their clonality, key role as driver mutation, association with poor prognosis undruggability, they represent attractive targets for immunotherapy. We have identified immunogenic peptides derived from codon 12 mutant (G12A, G12C, G12D, G12R, G12S G12V), which bind to HLA-A*02:01 HLA-A*03:01 elicit strong peptide-specific CD8+ T cell responses, indicating that there is an effective T-cell repertoire against these RAS-derived can...